Enanta assumed with a Buy at H.C. Wainwright

H.C. Wainwright analyst Brandon Folkes assumed coverage of Enanta (ENTA) with a Buy rating and $20 price target The shares offer a favorable risk/reward at current share levels, driven by the company’s upcoming clinical catalysts and diversified pipeline in virology and immunology, the analyst tells investors in a research note. The firm likes the stock into the respiratory syncytial virus Phase 2 data readout.